Lawrence Barr
Cardiovascular Disease · Elmhurst, ILNPI 1174560338
Payments from drug & device makers
Across 183 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Amgen$491
- Boehringer Ingelheim$399
- Novartis$303
- Abbott$222
- Chiesi USA, Inc.$208
- plus $1K from 12 others
What the payments were for
- Food & beverage$3,741100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 65 | $1,108 |
| Amgen | 24 | $491 |
| Boehringer Ingelheim | 10 | $399 |
| Novartis | 17 | $303 |
| Abbott | 10 | $222 |
| Chiesi USA, Inc. | 7 | $208 |
| Pfizer | 8 | $172 |
| Boston Scientific | 5 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $129 |
| AstraZeneca | 7 | $98 |
| Medtronic(2 entities) | 3 | $97 |
| Regeneron Healthcare Solutions, Inc. | 5 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Abiomed | 2 | $51 |
| Inari Medical, Inc. | 1 | $44 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$232
- CLEVIPREX$118
- WATCHMAN Access System$110
How this compares
$3,755 in reported general payments places this provider in the 60th percentile of 932 cardiovascular disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $48,229 |
| EntrestoSacubitril/Valsartan | 17 | $18,483 |
| XareltoRivaroxaban | 21 | $17,482 |
| Repatha SureclickEvolocumab | 18 | $12,638 |
| Metoprolol Succinate | 92 | $1,443 |
| Atorvastatin Calcium | 101 | $1,164 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $577 |
| Rosuvastatin Calcium | 33 | $494 |
| Carvedilol | 44 | $467 |
| ClopidogrelClopidogrel Bisulfate | 37 | $453 |
| Potassium Chloride | 22 | $371 |
| Ezetimibe | 12 | $235 |
| Lisinopril | 33 | $191 |
| Amlodipine Besylate | 23 | $158 |
| Metoprolol Tartrate | 21 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $172 | $48,22947 claims |
| NovartisEntresto | $303 | $18,48317 claims |
| Johnson & JohnsonXarelto | $1,108 | $17,48221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Elmhurst
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.